Northwest Biotherapeutics Stock Performance
| NWBO Stock | USD 0.28 0.01 3.70% |
Northwest Biotherapeutics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.25, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Northwest Biotherapeutics will likely underperform. Northwest Biotherapeutics right now secures a risk of 4.16%. Please verify Northwest Biotherapeutics treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Northwest Biotherapeutics will be following its current price movements.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Northwest Biotherapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy fundamental drivers, Northwest Biotherapeutics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 10 M | |
| Total Cashflows From Investing Activities | -6 M |
Northwest |
Northwest Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 28.00 in Northwest Biotherapeutics on October 24, 2024 and sell it today you would earn a total of 0.00 from holding Northwest Biotherapeutics or generate 0.0% return on investment over 90 days. Northwest Biotherapeutics is currently generating 0.0828% in daily expected returns and assumes 4.1627% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of otc stocks are less volatile than Northwest, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Northwest Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Northwest Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Northwest Biotherapeutics, and traders can use it to determine the average amount a Northwest Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0199
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | NWBO | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.16 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Northwest Biotherapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Northwest Biotherapeutics by adding it to a well-diversified portfolio.
Northwest Biotherapeutics Fundamentals Growth
Northwest OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Northwest Biotherapeutics, and Northwest Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Northwest OTC Stock performance.
| Return On Asset | -1.26 | ||||
| Profit Margin | 52.10 % | ||||
| Operating Margin | (54.95) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 1.05 B | ||||
| Price To Earning | 58.17 X | ||||
| Price To Sales | 858.96 X | ||||
| Revenue | 1 M | ||||
| EBITDA | 184.72 M | ||||
| Cash And Equivalents | 9.43 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 25.16 M | ||||
| Debt To Equity | (16.14) % | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (38.3 M) | ||||
| Earnings Per Share | (0.06) X | ||||
| Total Asset | 40.16 M | ||||
| Retained Earnings | (862.01 M) | ||||
| Current Asset | 24.1 M | ||||
| Current Liabilities | 64.93 M | ||||
About Northwest Biotherapeutics Performance
By examining Northwest Biotherapeutics' fundamental ratios, stakeholders can obtain critical insights into Northwest Biotherapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Northwest Biotherapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.Things to note about Northwest Biotherapeutics performance evaluation
Checking the ongoing alerts about Northwest Biotherapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Northwest Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Northwest Biotherapeutics has some characteristics of a very speculative penny stock | |
| Northwest Biotherapeutics had very high historical volatility over the last 90 days | |
| Northwest Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Northwest Biotherapeutics currently holds 25.16 M in liabilities. Northwest Biotherapeutics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Northwest Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Northwest Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Northwest Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Northwest to invest in growth at high rates of return. When we think about Northwest Biotherapeutics' use of debt, we should always consider it together with cash and equity. | |
| Northwest Biotherapeutics currently holds about 9.43 M in cash with (38.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Northwest Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Northwest Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Northwest Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Northwest Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Northwest Biotherapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Northwest Biotherapeutics' otc stock. These opinions can provide insight into Northwest Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.